Darifenacin XR Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Darifenacin XR Availability in 2026

If your patients are reporting difficulty filling their Darifenacin XR prescriptions, they're not wrong. While this medication isn't on the formal FDA shortage list, a combination of limited generic manufacturers, pharmacy stocking decisions, and supply chain fragility means real-world availability can be inconsistent.

This briefing covers the current state of Darifenacin XR supply, prescribing considerations, alternative therapies, and practical tools to help your patients access their medication.

Timeline: How We Got Here

Darifenacin (Enablex) was originally FDA-approved in 2004 as an M3-selective antimuscarinic for overactive bladder. It was marketed by Novartis and later by Warner Chilcott/Allergan.

• 2004: FDA approval of Enablex (Darifenacin ER) for OAB with symptoms of urge incontinence, urgency, and frequency.
• 2010-2012: Patents expired and generic versions entered the market.
• 2015-2020: Brand Enablex gradually phased out as generics took over. Only a small number of generic manufacturers remained.
• 2023-2024: The broader U.S. drug shortage crisis — affecting 300+ medications — strained pharmaceutical supply chains across the board, including less commonly prescribed generics.
• 2025-2026: Supply has stabilized but remains thin. Darifenacin ER is not formally in shortage but experiences sporadic availability gaps at retail pharmacies.

Prescribing Implications

The availability challenges with Darifenacin XR have several practical implications for prescribers:

Step Therapy and Prior Authorization

Many commercial and Medicare Part D plans now require step therapy for Darifenacin, typically requiring a trial of Oxybutynin or Tolterodine first. This has reduced overall Darifenacin prescription volume, which in turn has led pharmacies to reduce inventory — creating a feedback loop that makes the drug harder to find even for patients who need it.

When prescribing Darifenacin XR, consider:

• Documenting prior medication trials to expedite prior authorization
• Including clinical rationale for M3-selectivity (e.g., elderly patients where cognitive effects of less-selective agents are a concern)
• Using appeals processes when step therapy denials occur in patients with documented intolerance to first-line agents

Patient Population Considerations

Darifenacin's M3 selectivity offers a theoretical advantage in patients where non-selective antimuscarinics may pose cognitive risks. The 2023 AUA/SUFU guidelines note that anticholinergic burden should be considered, particularly in:

• Patients over 65, especially those with existing cognitive impairment or dementia risk
• Patients on multiple anticholinergic medications (cumulative burden)
• Patients who experienced CNS side effects on Oxybutynin or Tolterodine

For a comprehensive overview of the drug's pharmacology, see our article on how Darifenacin XR works.

Current Availability Picture

As of early 2026:

• FDA shortage status: Not listed
• Generic manufacturers: Limited to approximately 2-4 active producers
• Retail pharmacy stocking: Inconsistent. Large chains (CVS, Walgreens, Rite Aid) may not stock routinely. Independent and specialty pharmacies are more likely to carry or order it.
• Mail-order availability: Generally available through mail-order and online pharmacies including Cost Plus Drugs and Amazon Pharmacy.
• Dosage forms affected: Both 7.5 mg and 15 mg ER tablets may experience intermittent supply gaps, though 7.5 mg is generally easier to find.

Cost and Access Considerations

Cost remains a barrier for some patients, particularly those without insurance or on high-deductible plans:

• Average retail (cash) price: $250-$330 for 30 tablets
• With discount coupons (GoodRx, SingleCare): $20-$28 for 30 tablets — a 90%+ reduction
• Insurance copay range: $10-$50 depending on tier placement
• Medicare Part D: Generally covered; copay depends on plan phase

Encouraging patients to use prescription discount programs can significantly reduce out-of-pocket costs. Direct them to our patient savings guide for detailed information.

Tools and Resources for Providers

Medfinder for Providers offers real-time pharmacy stock data that can help your practice:

• Check availability before prescribing: Verify that a pharmacy near your patient has Darifenacin XR in stock before sending the prescription.
• Send prescriptions to in-stock pharmacies: Route e-prescriptions to pharmacies confirmed to have the medication, reducing callbacks and patient frustration.
• Monitor availability trends: Track which pharmacies in your area consistently stock Darifenacin ER.

Other resources:

• FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages — monitor formal shortage listings
• ASHP Drug Shortage Resource Center: For clinical guidance during supply disruptions
• Patient assistance programs: NeedyMeds and RxAssist for uninsured or underinsured patients

Alternative Therapies: Quick Reference

When Darifenacin is unavailable or not appropriate, consider these alternatives:

MedicationClassDoseM3 SelectivityGeneric AvailableApprox. Cost (with coupon)Solifenacin (Vesicare)Antimuscarinic5-10 mg dailyModerateYes$15-$40/moTolterodine ER (Detrol LA)Antimuscarinic2-4 mg dailyLowYes$10-$30/moOxybutynin ER (Ditropan XL)Antimuscarinic5-30 mg dailyLowYes$5-$15/moTrospium ER (Sanctura XR)Antimuscarinic60 mg dailyLowYes$20-$50/moMirabegron (Myrbetriq)Beta-3 agonist25-50 mg dailyN/AYes$30-$80/moVibegron (Gemtesa)Beta-3 agonist75 mg dailyN/ANo$350-$500/mo

For patients who need to switch, our alternatives guide provides patient-friendly information you can share.

Looking Ahead

The Darifenacin XR supply situation is expected to remain stable but thin through 2026. Key factors to watch:

• Generic manufacturer base: Any further consolidation or exits could create genuine shortages.
• Formulary shifts: If more plans drop Darifenacin from preferred tiers, prescription volume will decline further, potentially threatening the economic viability of generic production.
• New OAB therapies: The expanding OAB treatment landscape (Vibegron, combination approaches, neuromodulation) may shift prescribing patterns away from older antimuscarinics over time.

Final Thoughts

Darifenacin XR remains a clinically valuable option for OAB, particularly in populations where M3 selectivity matters. The supply picture isn't dire, but it requires awareness and proactive management.

Encourage your patients to use Medfinder for real-time stock checks, consider multi-pharmacy strategies for hard-to-find generics, and maintain familiarity with the alternative therapy landscape to minimize treatment interruptions.

For the patient-facing version of this update, see our patient shortage guide. For a step-by-step guide on helping patients find their medication, read how to help your patients find Darifenacin XR in stock.